Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ICER To Open Cost Effectiveness Models To Drug Firms During Review Process

Apr 12 2018

• By Cathy Kelly

Institute For Clinical And Economic Review

Related Content

Open-Source Rx Value Model Designed To Encourage 'More Productive' Discussions

Jan 23 2018

Related Companies

Amgen, Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

Eli Lilly and Company

AbbVie Inc.

Neurocrine Biosciences, Inc.

Eli Lilly and Company

Additional Topics

United States Pricing Debate Policy Cost Effectiveness BioPharmaceutical

More from Pricing Debate

More from Market Access

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window